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ABSTRACT
Colorectal cancer (CRC) is the third most common cancer and the
second leading cause of cancer-related deaths worldwide. Most
CRC deaths are the result of progression of metastases. The as-
sessment of metastases is done using the RECIST criterion, which
is time consuming and subjective, as clinicians need to manually
measure anatomical tumor sizes. AI has many successes in image
object detection, but often suffers because the models used are
not interpretable, leading to issues in trust and implementation in
the clinical setting. We propose a framework for an AI-augmented
system in which an interactive AI system assists clinicians in the
metastasis assessment. We include model interpretability to give
explanations of the reasoning of the underlying models.
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1 INTRODUCTION
Colorectal cancer (CRC) is the third most common cancer and
the second leading cause of cancer-related deaths worldwide [5].
Most cancer deaths are the result of progression of metastases.
Approximately 50% of CRC patients will develop metastases to
the liver (CRLM) [1, 8]. Patients with liver-only colorectal metas-
tases can be treated with curative intent. Complete surgical re-
section of CRLM is considered the only method with a chance to
cure these patients [4, 7, 20]. Only 20% of the patients with CRLM
present with resectable CRLM [2, 6, 22, 29]. Initially-unresectable
liver metastases can become resectable after downsizing the lesions
via systemic therapy. However, there is no consensus regarding the
optimal systemic therapy regime. The effect of systemic treatment
varies between patients, some have total response and others show
progression of disease [2, 21]. Moreover, systemic therapy has a lot
of side effects due to its cytotoxicity [18].
In clinical oncology, the selection and monitoring of treatment
is crucial for effective cancer treatment and for the evaluation of
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new drug therapies. Accordingly, assessment of patient response to
treatment is a crucial feature in the clinical evaluation of systemic
therapy. The widely accepted and applied criterion for such assess-
ment is the Response Evaluation Criteria In Solid Tumors (RECIST),
which aims to measure the objective change of anatomical tumor
size. The RECIST assessment is performed by measuring changes
in one-dimensional (1-D) diameter in two target lesions before and
after therapy [10]. Though RECIST is a clinical standard worldwide,
it is highly limited. Currently, it is not possible to predict clinical
outcome based on tumor response assessment (RECIST) and patient
characteristics in individual patients. A meta-analysis revealed that
inter-observer variability in RECIST measurement may exceed the
20% cut-off for progression, resulting in potential misclassification
of diagnosis (stable disease or progression) [30]. A further prob-
lem of RECIST is the subjectivity and variability in selecting target
lesions.
1.1 Assessment Automation
One of the goals of this project is to more accurately and efficiently
assess tumor response. Automated medical image processing al-
lows more objective analysis of clinically relevant imaging features.
Machine learning methods like object detection models trained
on clinical data can be used to detect tumor lesions and automate
systemic therapy response assessment. However, fully automated
systems directly based on object detection models are not ideal
under current circumstances, for reasons including
• Accuracy concerns: Modern general purpose object detection
methods can only achieve 30% to roughly 75% mean average
precision (mAP), depending on the dataset they are tested on[13].
Specialized models trained specifically for lesion detection may
achieve better accuracy, but will still make mistakes. Incorpo-
rating professional knowledge and feedback from clinicians can
significantly improve detection accuracy.
• Lack of interpretability: Most of the high-performance object
detection models are based on deep learning, which are often
considered black-box models. However, it is important to commu-
nicate the reason behind decisions to the physician prescribing
treatment plans and to the patient. A system without the ability
to explain its decisions is not desirable in the clinical setting.
Thus, in this paper we propose an interactive system, in which we
use machine learning object detection models along with model
interpretability and natural language generation to augment the ef-
ficacy and accuracy of clinicians in lesion detection and assessment.
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Model interpretability with natural language generation acts to pro-
vide trust and understanding of the underlying machine learning
object detection models.
2 RELATEDWORK
2.1 Clinical studies
Artificial intelligence is quickly moving forward in many fields,
including in medicine. Deep learning techniques have delivered
impressive results in image recognition. Radiology and pathology
are medical specialties that create and evaluate lots of medical
images. Multiple studies in these specialties have used artificial
intelligence to mimic or augment human capabilities.
Masood et al. [17] propose a computer-assisted decision sup-
port system with the potential to help radiologists in improving
detection and diagnosis decision for pulmonary cancer stage classi-
fication. Wang et al. [28] show that using a deep learning model
for automated detection of metastatic breast cancer in lymph node
biopsies reduces the error rate of pathologists from over three per-
cent to less than one percent. Hamm et al. [11] use a convolutional
neural network for fast liver tumor diagnosis on multi-phasic MRI
images.
While these initial results are positive, substantial translation
or implementation of these technologies into clinical use has not
yet transpired [12]. Beyond building AI algorithms, applying them
in daily clinical practice is complex [9]. Key challenges for the
implementation include data sharing, patient safety, data standard-
ization, integration into complex clinical workflows, compliance
with regulation, and transparency [12]. Transparency of complex
AI algorithms is of great importance for clinicians. If a medical doc-
tor cannot understand the outcome of an algorithm, then the doctor
will be unable to explain the outcome to a patient. Technologies
that help explain complex AI algorithms have an important role in
acceptance of AI by the medical community.
2.2 Model interpretability
In our proposed framework there is a need for an applicable model
interpretability method. The majority of methods for model inter-
pretability come in three forms: inherently-interpretable models
[3, 15, 27], methods for interpreting existing models [19, 25]), and
post-hoc investigations [16, 23, 24, 26]. In the current framework,
we use a segmentation convolutional neural network model for
lesion detection in CT images for the CRLM patients. To give ex-
planations of this model, we use Shapley values, a post-hoc, model-
agnostic interpretability method. The model-agnostic nature of the
Shapley values gives us the flexibility to substitute better perform-
ing models in future research.
The Shapley Values were originally introduced in game theory
as a way to determine the individual contributions of players in a
collaborative game. In model interpretability the Shapley values are
used to measure the individual contributions of the input variable
values of a single observation to a model’s prediction. Recent work
in this area includes [16, 26]. Image models use as inputs a series
of pixel values. Assigning Shapley values to these pixels creates a
gradient over an image indicating regions of an image that lead to
or detract from lesion detection probabilities. This gradient is very
easy to understand, which makes Shapley values a natural method
for the clinician-collaboration framework.
3 PROPOSED FRAMEWORK
In this section we propose a system with clinician interaction for
high accuracy lesion detection and measurement. The proposed
system is summarized in Figure 1.
The images from a CT scan are sent to an automated report gen-
eration system. The report generation system’s purpose is to create
an interactive and coherent report highlighting possible lesions.
This report will allow a clinician to quickly confirm or overwrite the
detections made by the automated system. The report generation
system consists of three modules: a lesion detection module, an
interpretability module, and a natural language generation module.
The lesion detection module processes the scan images and labels
all potential lesions. Note that we can use any high-accuracy ob-
ject detection model as the detection module. The detected lesions
are sent to the interpretability module to generate visual explana-
tions that highlight important decision areas, which can help the
clinician make better informed decisions. The natural language gen-
eration module then collects information from previous modules
and generates a report for the clinician.
Once a report is generated, a clinician then reviews the report,
confirming or rejecting each individual detection. The clinician can
also add new lesion detections missed by the automated system.
During the review process, the clinician can interact with the inter-
pretability module, review explanations for detected lesions, and
request explanations for new areas as indicated by the clinician.
Once all detections are confirmed or rejected, the scan image is
sent to the automated measuring system, where information like
lesion count, location, and diameter is recorded.
CT Scan Image 
Lesion Detection 
Module 
Natural Language 
Generation Module 
Interpretability 
Module 
Detected Lesions 
Explanations 
Clinician Review 
Final Lesion 
Count and 
Measurement 
Automated Report  
Generation System 
Automated 
Measuring System 
Clinician Interaction 
Interpretability 
Module 
Lesion Detection Report 
Figure 1: Flow chart of the proposed system
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4 HYPERSHAP (HYPERPARAMETERIZED
SHAPLEY VALUE ESTIMATION)
The interpretability module in our proposed framework uses Shap-
ley values. We propose a novel and deterministic approximation to
the Shapley values for efficient computation.
The calculation of the Shapley values for the ith variable of an
instance of interest, which we call a query q, given a predictive
model f : Rm → R is
ϕi =
∑
z ∈[0,1]m,z i=0
(m − |z | − 1)!|z |!
m!
(
Ez+e i [(f (x)] − Ez [f (x)]
)
,
where the expectation Ez [f (q)] = 1n
∑
x ∈X f (τ (q,x , S)) is com-
puted over all observations x in a data set X with n total observa-
tions. The function τ (q,x , S) =
{
qi i ∈ S
xi i < S
, and the relationship
between z and S is zi =
{
1 variable i ∈ S
0 variable i < S
.
S represents a subset of variables used in the model training.
The summation in the Shapley value computation is over all z ∈
[0, 1]m ,zi = 0, that is to say, all subsets of variables that are not
the variable of interest.
It is important to note that the Shapley value computation re-
quires all subsets of variables, of which there are 2m . This com-
putation complexity makes direct computation infeasible. Instead,
we rely on a deterministic approximation that uses only allowed
subsets of variables as determined by a hyperparameter χ , leading
to the name HyperSHAP. We use a deterministic approximation to
ensure stability in explanations, while still achieving high accuracy
of the Shapley values.
Algorithm 2 describes the full HyperSHAP computation for a
value of χ , using Algorithm 1, which computes the expectations.
Algorithm 1 Shapley Expected Values
1: input: training data X t ∈ Rn×m , query data q ∈ Rm , model
function f (·) : Rm → R, selection matrix Z ∈ {0, 1}c×m
2: initialize: µ = 0c×1 be an all-zero vector
3: for j = 1 . . . , c do
4: initialize: Xz = [ ]
5: Let z = Z[j, :] be the jth row of Z
6: for i = 1 . . . ,n do
7: Compute xz = τ (q,X t[i, :],z) using the ith row of X t
8: Xz =
[
Xz
xz
]
9: end for
10: Compute y ∈ Rn , where yt = f (Xz[t, :]), t = 1, . . . ,n
11: µ j =
1
n1
⊤
n×1y
12: end for
13: output: µ
5 PRELIMINARY RESULTS
5.1 Clinical Data
The first phase of this project aims to improve the response assess-
ment to systemic therapy of CRLM patients by applying advanced
Algorithm 2 HyperSHAP
1: input: training data X t ∈ Rn×m , query data q ∈ Rm , model
function f (·) : Rm → R, approximation depth χ
2: initialize: Z = [ ]
3: for k = 0, . . . , χ ,m − χ , . . . ,m do
4: Let Zk ∈ {0, 1}(mk )×m be the selection matrix whose rows
form the set {z ∈ {0, 1}m : |z | = k}
5: Z =
[
Z
Zk
]
6: end for
7: Use Algorithm 1 to compute µ with Z
8: Let c be the number of rows in Z
9: for i = 1, 2, . . . ,m do
10: a = Z[:,i] ∈ {0, 1}c , the ith column of Z
11: b = Z[:, j,i]1(m−1)×1 ∈ Nc×1, the row sum of Z excluding
the ith column
12: v = 0c×1
13: for j = 1, . . . , c do
14: vj =
{
(2aj − 1)wχ (bj ), if bj ≤ χ − 1 or bj ≥ m − χ
0, otherwise
wherewχ (bj ) =
{ bj !(m−bj−1)!
m! · m2χ , χ < ⌈m/2⌉
bj !(m−bj−1)!
m! , otherwise.
15: end for
16: ϕi = v⊤µ
17: end for
18: ϕ0 = f (q) −∑mi=1 ϕi
19: output: ϕ0,ϕ1, . . . ,ϕm
analytics to medical imaging and clinical data. All patient data used
were collected as part of the multicenter randomized clinical trial
CAIRO5 [14]. This ongoing study aims to downsize tumor burden
in the liver and make local treatment with curative intent feasible
for initially unresectable colorectal liver metastases, in order to
improve (disease-free) survival. The data consisted of diagnostic
imaging (CT images) before and after systemic therapy, evaluated
by a nationwide expert-panel. The CT-images from 52 patients
were used for segmentation of the liver and liver metastases by
an expert radiologist. The expert segmentations were performed
semi-automatically using the Philips® IntelliSpace Portal software.
A total of 1380 liver metastases were segmented, resulting in the
3-D organ contours of the liver and all metastases. From each tumor,
each three-dimensional pixel (voxel) is available for analytics.
5.2 Model Training and Interpretation
We built a deep-learning image segmentation model targeting la-
beled lesion regions on the CT images. For each new test CT image,
we use the deep-learning model to predict lesion regions, and then
calculate the Shapley values for the deep-learning model on the de-
tected lesion regions in the image. Positive Shapley values indicate
pixels that contribute positively towards the predicted probability
of a lesion, while negatively Shapley values indicate pixels that
contribute negatively towards the model’s predicted probability of
a lesion. By viewing the area that contributes towards the predicted
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probability of a lesion, a clinician can see what area of the CT image
the deep-learning model thinks is indicative of a lesion in the liver.
In Figure 2 we show a sample report generated using the pro-
posed framework.
Selected Lesion Explanation of Selected 
Lesion 
The model has found three potential lesions (orange 
boxes) from the slice. The selected lesion area and its 
explanation are shown above. The red pixels in the 
explanation highlight the area that contributes positively 
to the lesion prediction according to the model. The green 
pixels highlight the area that detracts from the model’s 
predicted probability of the lesion. Slice 121 
✔	
✖	
i 
✔	
✖	
i 
✔	
✖	
i 
Figure 2: A sample report. The clinician can confirm or re-
ject each detected lesion by clicking the green or red but-
ton next to the bounding box. Clicking the orange button
(labeled with letter “i”) will show explanations for the cor-
responding image patch for review. The clinician can also
label new areas as lesions and request explanations.
6 CONCLUSION
Current lesion detection andmeasurement systems are not clinician-
efficient, taking large amounts of clinicians’ time. These systems
also suffer from significant inter-clinician variability. The proposed
system optimizes the use of clinicians’ time by quickly identifying
potential lesions and providing interpretation as to why the model
provided such a prediction. By automating a portion of the lesion
detection task, our framework can reduce inter-clinician variability.
Our initial experiments have shown promise both in the abil-
ity to detect lesions and the ability to explain the predictions of a
lesion detection model. Future work includes improving the detec-
tion model, improving the interaction system with clinicians, and
validating our AI-augmented framework through clinical trials.
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